Translate
Rigel Pharmaceuticals Inc
About
Rigel Pharmaceuticals Inc (NASDAQ:RIGL) — investor relations, events, news, and company updates on 6ix.
Latest News
Mar 31 2026
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
Mar 3 2026
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Feb 24 2026
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update
Feb 3 2026
Rigel Appoints Michael P. Miller to the Board of Directors
Jan 12 2026
Rigel Provides Business Update and 2026 Outlook
Financials
Revenue
$294.28 M
Market Cap
$505.42 M
P/E Ratio
1.40
EPS
19.48